Maze治疗公司报告季度损失,缺估,但保留“Buy”评级。 Maze Therapeutics reported a quarterly loss, missing estimates, but retains a "Buy" rating.

Maze治疗学公司(NASDAQ:MAZE)报告,最近季度每股损失18.32美元,缺少分析师的估计损失10.72美元。 Maze Therapeutics (NASDAQ:MAZE) reported a loss of $18.32 per share for the latest quarter, missing analyst estimates by $10.72. 尽管收入亏损,公司股票仍维持“Buy”评级,目标价为25.67美元。 该公司的股票最高一年,为17.00美元。 Despite the earnings miss, the company's stock, which has a one-year high of $17.00, maintains a "Buy" rating with a consensus target price of $25.67. Maze Therapeutics 专注于开发针对肾脏、心血管和相关代谢疾病的精准药物。 Maze Therapeutics specializes in developing precision medicines for renal, cardiovascular, and related metabolic diseases.